Renal cell carcinoma (RCC) is the third most common urological malignancy and one of the most refractory malignancies due to a metastasis rate of up to 25% at presentation and the lack of a curative therapy. Generally, RCC is highly resistant to conventional chemotherapy and radiation therapy and the mortality from RCC exceeds 100,000 per year worldwide.
GENOMINE Inc. offers the GenoPlexMAP Human Renal Cell Carcinoma detection kit. The Cancer Biomarker Panel includes 3-Plex assay, which simultaneously measures three serum biomarkers, Nicotinamide N- metyltransferase (NNMT), Non-metastatic cells 1 (NM23A) and L-plastin (LCP1).
The combination of the three serum biomarkers that discriminate between disease-free and Renal Cell Carcinoma patients was characterized and validated by GENOMINE Inc. and Yonsei University Medical School. Using a scoring algorithm, the profile of three biomarkers in circulation was used to detect all stages of Renal Cell Carcinoma patients with high sensitivity and accuracy. The assays can be used to quantify these biomarkers in serum, plasma.